独家消息，美国众议院一个委员会正对艾伯维公司（AbbVie）与默沙东（Merck）在中国进行的药物临床试验展开调查。此举旨在查明这些试验活动是否在客观上增强了中国的军事能力。
调查的核心焦点在于，这些跨国药企在华开展的生物医学研究，其产生的科学数据与技术成果，是否存在被转移或应用于军事领域的潜在可能。委员会试图评估此类合作是否间接助力了中国在生物技术及相关领域的军事进展。
目前，艾伯维与默沙东方面尚未就此次调查作出公开回应。此事凸显了在中美科技竞争加剧的背景下，美国立法机构对商业与科研合作可能涉及的国家安全风险正给予前所未有的审视。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.